Trial Profile
A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 01 Sep 2023
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Lenvatinib (Primary)
- Indications CNS cancer; Diffuse intrinsic pontine glioma; Ewing's sarcoma; Glioma; Neuroectodermal tumours; Rhabdomyosarcoma; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Eisai Inc
- 08 Nov 2022 Status changed from active, no longer recruiting to completed.
- 18 Jul 2022 Planned End Date changed from 31 Dec 2022 to 30 Sep 2022.
- 18 Jul 2022 Planned primary completion date changed from 31 Jul 2022 to 30 Sep 2022.